Cambrex (CBM) Shares Up 5%

Shares of Cambrex Co. (NYSE:CBM) shot up 5% on Thursday . The company traded as high as $40.27 and last traded at $40.19. 609,599 shares were traded during mid-day trading, an increase of 30% from the average session volume of 467,463 shares. The stock had previously closed at $38.27.

Several brokerages recently commented on CBM. Zacks Investment Research raised shares of Cambrex from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research report on Thursday, January 31st. Robert W. Baird began coverage on shares of Cambrex in a research report on Thursday, November 15th. They set an “outperform” rating on the stock. First Analysis raised shares of Cambrex from an “outperform” rating to a “strong-buy” rating and cut their price objective for the company from $73.00 to $63.00 in a research report on Friday, November 9th. TheStreet downgraded shares of Cambrex from a “b” rating to a “c+” rating in a research report on Monday, December 3rd. Finally, ValuEngine raised shares of Cambrex from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $56.88.

The company has a current ratio of 3.93, a quick ratio of 2.86 and a debt-to-equity ratio of 0.46. The company has a market cap of $1.29 billion, a PE ratio of 14.51, a PEG ratio of 1.29 and a beta of 2.45.

Cambrex (NYSE:CBM) last posted its earnings results on Wednesday, February 13th. The biotechnology company reported $1.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. The business had revenue of $212.30 million for the quarter, compared to analysts’ expectations of $182.49 million. Cambrex had a net margin of 17.37% and a return on equity of 14.74%. The business’s revenue for the quarter was up 16.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.26 EPS. Equities analysts forecast that Cambrex Co. will post 2.97 earnings per share for the current year.

In other Cambrex news, COO Shawn Cavanagh sold 6,769 shares of the company’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $37.60, for a total transaction of $254,514.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Gregory Sargen sold 5,802 shares of the company’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $37.45, for a total transaction of $217,284.90. The disclosure for this sale can be found here. 2.42% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Enlightenment Research LLC bought a new position in shares of Cambrex in the 4th quarter worth approximately $30,000. Private Capital Group LLC lifted its stake in shares of Cambrex by 25.9% in the 4th quarter. Private Capital Group LLC now owns 1,503 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 309 shares during the period. NumerixS Investment Technologies Inc bought a new position in shares of Cambrex in the 4th quarter worth approximately $79,000. Bruderman Asset Management LLC bought a new stake in Cambrex during the 4th quarter worth approximately $125,000. Finally, BlueMountain Capital Management LLC bought a new stake in Cambrex during the 3rd quarter worth approximately $144,000.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2019/02/22/cambrex-cbm-shares-up-5.html.

About Cambrex (NYSE:CBM)

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

See Also: What are CEFs?

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.